Two proton beam therapy (PBT) centres are being developed nationally, one at The Christie and the other at University College London Hospitals NHS Foundation Trust.
They are both being funded by a £250 million government investment. Interserve was appointed to design and deliver the Manchester PBT centre through a rigorous P21+ procurement process.
The state of the art five storey building will provide:
The building is designed to be future proofed - the research room can in future be equipped with a treatment gantry, a structure to support the equipment that delivers the treatment, if required.
Prior to appointment Interserve took an innovative approach to develop UK PBT expertise, taking 11 flights and travelling 20,239 miles around the world to visit 10 PBT centres and 6 equipment vendors, embedding international expertise, capturing learning and sharing best practice.
By designing the facility around the equipment, and being brought in very early in the equipment procurement stage, Interserve is helping The Christie to drive the project’s costs down and offer value for money.
Using Building Information Modelling (BIM)
Building Information Modelling (BIM) technology has played a crucial role in the design and construction of the proton beam therapy centre. Interserve, HKS architects, Arup - a firm of designers, planners, engineers, consultants and technical specialists - and equipment suppliers all produced BIM models which have been integrated into one version to give a 4D representation of the project, creating theoretical savings of around £1.95 million through early clash detection.
The scale of the project is immense, with a requirement for material and skills to deliver the monolithic pour of 17,000m3 of concrete and 1700 tonnes of reinforcement over 12 months, accommodating required thicknesses of between 4 and 6m. The biggest single concrete pour on the site in the course of one day will be 648m3, equivalent to 105 concrete wagons.
The new facilities will mean that up to 750 patients a year with complex cancers will have the opportunity to benefit from this treatment.